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A B S T R A C T   
Myosin heavy chain-IIB (MyHC-IIB; encoded by MYH4 or Myh4) expression is often associated with muscle 
hypertrophic growth. Unlike other large mammals, domestic pig breeds express MyHC-IIB at both the mRNA and 
protein level. 
Aim: To utilise a fluorescence-based promoter-reporter system to test the influence of anabolic and catabolic 
agents on increasing porcine MYH4-promoter activity and determine whether cell hypertrophy was subsequently 
induced. 
Methods: C2C12 myoblasts were co-transfected with porcine MYH4-promoter-driven ZsGreen and CMV-driven 
DsRed expression plasmids. At the onset of differentiation, treatments (dibutyryl cyclic-AMP (dbcAMP), Des 
(1–3) Insulin-Like Growth Factor-1 (IGF-I), triiodo-L-thyronine (T3) and dexamethasone (Dex)) or appropriate 
vehicle controls were added and cells maintained for up to four days. At day 4 of differentiation, measurements 
were collected for total fluorescence and average myotube diameter, as indicators of MYH4-promoter activity 
and cell hypertrophy respectively. 
Results: Porcine MYH4-promoter activity increased during C2C12 myogenic differentiation, with a marked in-
crease between days 3 and 4. MYH4-promoter activity was further increased following four days of dbcAMP 
treatment and average myotube diameter was significantly increased by dbcAMP. Porcine MYH4-promoter ac-
tivity also tended to be increased by T3 treatment, but there were no effects of Des(1–3) IGF-I or Dex treatment, 
whereas average myotube diameter was increased by Des(1–3) IGF-I, but not T3 or Dex. 
Conclusion: Porcine MYH4-promoter activity responded to dbcAMP, Des(1–3) IGF-I and T3 treatment in vitro as 
observed previously in reported in vivo studies. However, we report that increased MYH4-promoter activity was 
not always associated with muscle cell hypertrophy. The fluorescence-based reporter system offers a useful tool 
to study muscle cell hypertrophic growth.   
1. Introduction 
Skeletal muscle tissue demonstrates a high level of plasticity and the 
ability to dynamically respond to its environment. The basic molecular 
structure of skeletal muscle is highly conserved across species and 
comprises of contractile motor units called sarcomeres [1]. Sarcomeres 
are composed of two major proteins: actin and myosin. Myosin makes up 
the largest proportion of the sarcomeres in the form of myosin heavy 
chains (MyHC), essential myosin light chains and regulatory myosin 
light chains [2]. The four main MyHC isoforms expressed in adult 
skeletal muscle are MyHC-I, -IIA, -IIX and -IIB, and each confers different 
morphological, enzymatic and functional characteristics [3]. With the 
exception of rodents, mammalian muscle fibres generally express mul-
tiple MyHC isoforms and are able to transition sequentially in response 
to mechanical stimuli (I ↔ IIA ↔ IIX ↔ IIB). MyHC-I (encoded by MYH7 
gene) is indicative of a slow-twitch oxidative muscle fibre phenotype, 
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whereas MyHC-IIB (encoded by MYH4 gene) indicates a fast-twitch 
glycolytic phenotype [4]. Interestingly, all mammals carry the MYH4 
gene but most large mammals (e.g. humans, cattle, sheep) do not express 
MyHC-IIB at the protein level [5–7]. Pigs are the exception, particularly 
domestic pig breeds which have been reported to express much higher 
levels of MyHC-IIB in their skeletal muscle than wild pigs [8]. Increased 
expression of MyHC-IIB is often associated with muscle hypertrophy, 
therefore this characteristic has most likely developed as a result of 
intensive breeding for enhanced muscle growth traits [8,9]. Similarly 
domestic pigs administered with Ractopamine, a beta-adrenergic re-
ceptor agonist (BA), demonstrate significant increases in both muscle 
weights and MYH4 mRNA expression, whilst MYH1 (encodes MyHC-IIX) 
and MYH2 (encodes MyHC-IIA) mRNA are reduced [10,11]. 
We previously showed that the MyHC isoforms are expressed in two 
distinct cohorts during C2C12 myogenic differentiation, where Myh4 
mRNA expression was associated with mature, well differentiated 
myotubes following 3–4 days of differentiation [12]. We also previously 
reported the use of a porcine MYH4-promoter-reporter system that can 
be utilised in C2C12 cells to study the transcriptional regulation of the 
porcine MYH4-promoter activity [13] and changes in myotube diameter 
[14]. BA, growth hormone (GH), triiodothyronine (T3) and dexameth-
asone (Dex) are well known anabolic and catabolic agents. In this study 
we aimed to utilise these agents to characterise the response of the 
porcine MYH4-promoter-reporter system, and the association with 
average myotube diameters, as a potential in vitro model system for 
identifying novel anabolic and catabolic agents for pigs. 
As indicated above, BAs like Ractopamine have previously been 
shown to induce both muscle hypertrophy and a shift to a fast-glycolytic 
MyHC-IIB phenotype in pigs [10,11,15,16], cows [17,18], sheep [19], 
rats [20–23] and mice [14,24]. In the present study, dibutyryl 3′,5′-cy-
clic adenosine monophosphate (dbcAMP), the cAMP analogue, was used 
to mimic the downstream intracellular signalling response to BA treat-
ment, as previous studies have shown variable responses of cultured 
muscle cells to BA treatment [25]. We hypothesised that dbcAMP would 
increase both MYH4-promoter activity and average myotube diameters 
in the porcine MYH4-promoter reporter system. 
Treatment of adult pigs with GH has been shown to increase muscle 
fibre size, but with no effect on fibre-type composition [26–30]. We 
previously reported that GH administration also had no effect on the 
proportion of MyHC isoforms in both pigs [11] and sheep [19]. 
Insulin-like Growth Factor-I (IGF-I) is considered the main active 
component of the GH-IGF axis [31]. In this study we used Des(1–3) IGF-I 
as it is reported to induce similar responses to IGF-I treatment in vitro 
[32]. Des(1–3) IGF-I has a similar binding affinity as IGF-I to the 
IGF-type 1 receptor [33], but has a much lower binding affinity for IGF 
binding proteins (IGFBPs) [34]. Hence using Des(1–3) IGF-I avoided any 
possible effects of IGFBPs present, and we hypothesised that it would 
increase average myotube diameters, whilst having no effect on 
MYH4-promoter activity. 
The active form of thyroid hormone (3,3’,5-Triiodo-L-thyronine or 
T3) has previously been shown to induce a fibre-type shift in adult rats 
administered T3 for 4 weeks, with an increase in the proportion of fast- 
twitch type-II fibres and a reduction in slow-twitch type-I fibres [35]. 
Prolonged treatment of rats with T3 for 6 weeks resulted in a reduction 
in body weight, muscle weights and muscle fibre cross sectional area 
[36–38]; however the decrease in muscle mass could be due to the in-
crease in whole body energy expenditure observed, rather than a direct 
effect of T3 alone on muscle atrophy. Thus, we hypothesised that T3 
would increase MYH4-promoter activity, but either have no effect or 
possibly decrease average myotube diameters. 
Lastly, Dex was used as a potential catabolic agent. Dex is a synthetic 
glucocorticoid that is more potent than endogenous corticosterone and 
concentrations up to approximately 120 nM are thought to be within the 
physiological range [39]. Chronic, prolonged exposure to glucocorti-
coids has been reported to induce muscle atrophy [40,41]. Dex treat-
ment for 5 days caused a reduction in both body weight and EDL muscle 
mass in rats, associated with a decrease in cross sectional area of both 
type-I and type-II fibres [42]. Similarly, long-term Dex treatment of 
growing pigs resulted in significantly reduced growth rates, body weight 
and lean mass percentage [43]. Therefore, we hypothesised that Dex 
would reduce average myotube diameters, but have no effect on 
MYH4-promoter activity in the porcine MYH4-promoter reporter 
system. 
2. Materials and methods 
2.1. Materials and compounds 
High glucose (25 mM) Dulbecco’s modified eagle’s medium (DMEM; 
D5796), cell culture grade water, N6,2′-O-Dibutyryladenosine 3′,5′-cy-
clic monophosphate sodium salt (dbcAMP), dexamethasone (Dex) and 
3,3′,5-Triiodo-L-thyronine sodium salt (T3) were all purchased from 
Sigma-Aldrich (Poole, UK). Human Recombinant Des(1–3) IGF-I was 
purchased from SourceBioscience and other cell culture reagents were 
purchased from Fisher Scientific (Loughborough, UK). Compounds were 
prepared as follows: dbcAMP was dissolved in cell culture grade water at 
100 mM, Des(1–3) IGF-I in 0.1 M acetic acid at 100 μg/ml, T3 in 0.1 M 
sodium hydroxide at 100 nM and Dex in absolute ethanol at 10 mM. 
Compounds were filter-sterilised through a 0.2 μm filter and aliquots 
stored at − 20 ◦C. 
2.2. Cell culture methods 
C2C12 cell stocks were originally purchased from the European 
Collection of Authenticated Cell Cultures (ECACC; 91031101) and 
checked regularly for mycoplasma. C2C12 cells were cultured in a hu-
midified incubator at 37 ◦C with 5% CO2 and were used between pas-
sages 14–18 for experiments. C2C12 myoblasts were seeded into growth 
media (High glucose (25 mM) DMEM supplemented with 10% foetal 
bovine serum and 1% penicillin/streptomycin, P/S) at 25,000 cells per 
well onto 24-well plates. Approximately 1 kb of the porcine MYH4- 
promoter (− 961bp to +32bp, relative to the transcriptional start site) 
was cloned into a ZsGreen1-1 expression vector (Clontech) as described 
previously [13]. The day after seeding (~50–60% confluence), C2C12 
myoblasts were co-transfected with MYH4-ZsGreen promoter-reporter 
plasmid (200 ng per well) and CMV-DsRed-Express-N1 (100 ng per 
well) at a ratio of 3:1 for plasmid DNA:FuGENE® (E2311, Promega). The 
following day, cells (~80% confluence) were switched to differentiation 
media (DM; DMEM supplemented with 2% horse serum and 1% P/S) 
with or without treatments, determined as day 0. 
The following doses used were based on previous studies, 1 mM for 
dbcAMP [44], 20 ng/ml for Des(1–3) IGF-I [32,45], 10 nM for T3 [46] 
and 10 μM for Dex [47]. Immediately prior to treatment, compounds 
and respective vehicle controls were diluted to working concentrations 
either directly into pre-warmed DM (dbcAMP and T3) or initially in 
phosphate buffered saline (for Des(1–3) IGF-I and Dex) followed by a 
further dilution in DM. Culture media and treatments were refreshed 
every 48 h. Measurements for total fluorescence per well and average 
myotube diameter were performed on consecutive days or on day 4 of 
differentiation only. 
2.3. Measurement of porcine MYH4-promoter activity 
Porcine MYH4-promoter activity was measured as total fluorescence 
Table 1 
Typhoon Trio + parameters for total fluorescence per well quantification.  







1 Blue ZsGreen 488 520 Medium 
2 Green DsRed 532 580 Medium  
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per well using a Typhoon Trio + scanner (GE Healthcare). Cell culture 
plates were scanned as indicated in Table 1, with focal plane set to +3 
mm and image quality captured at 100 μm. Scan time was approxi-
mately 20 min per cell culture plate (1 × 24-well plate). ‘Integrated 
Density’ for the set area of each well was quantified using ImageJ 
software. The fluorescence intensity of ZsGreen for each well was nor-
malised to DsRed (i.e. ZsGreen ÷ DsRed) to account for differences in 
transfection efficiency. Wells seeded with C2C12 cells, but not trans-
fected, were used as a ‘background control’ to account for auto- 
fluorescence. All data related to porcine MYH4-promoter activity can 
be found in Supplementary Datafile 1. 
2.4. Measurement of myotube diameters 
Immediately after the scan of total fluorescence per well (on day 4 
differentiation), fluorescence images of live cells were captured using a 
Leica inverted fluorescence microscope and Leica Application Suite 
software. Three to five fields of view were captured per well, then from 
each view average diameter of MYH4-expressing myotubes was deter-
mined for 10 randomly selected myotubes. Using ImageJ, the diameter 
was measured at approximately 25, 50 and 75% along the total length of 
each myotube as described previously [14]. Images were blind labelled 
to remove bias for the analysis. All data related to myotube diameter 
measurements can be found in Supplementary Datafile 2. 
2.5. Statistical analysis 
Statistical analysis was performed using GenStat (17th edition) sta-
tistical software. For total fluorescence measurements taken on the same 
samples for consecutive days, a repeated measures two-way analysis of 
variance (ANOVA) was performed (time x treatment). For total fluo-
rescence measurements collected at a single time-point, a Student’s t- 
test was performed to compare the treatment to its vehicle control. For 
myotube diameter measurements collected at a single time-point, one- 
way ANOVA was performed and blocked according to the individual 
‘well’ for different fields of view. Data are presented as means ±
standard error of the mean (SEM). 
3. Results 
3.1. Effect of dbcAMP on porcine MYH4-promoter activity and diameter 
of MYH4-expressing myotubes 
There was a significant time × treatment interaction for MYH4- 
promoter activity during myogenic differentiation (P < 0.001; Fig. 1a). 
Porcine MYH4-promoter activity (i.e. ZsGreen fluorescence) was only 
observed in differentiated myotubes and increased gradually with time 
as myotubes developed and matured, being low at day 2 of differenti-
ation but with a slight increase by day 3 and followed by a marked in-
crease between days 3 and 4. Treatment with dbcAMP increased MYH4- 
promoter activity at day 4 of differentiation (32%) relative to the water 
vehicle control. This was supported by images shown in Fig. 1b. Simi-
larly, average myotube diameter was also significantly increased (43%; 
P < 0.001; Fig. 1c) after four days of treatment with dbcAMP compared 
to water. 
As dbcAMP was observed to significantly increase both MYH4-pro-
moter activity and average myotube diameter of MYH4-expressing 
myotubes compared to water, dbcAMP and water were used in subse-
quent experiments to act as positive controls for both measurements. 
3.2. Effect of Des(1–3) IGF-I on porcine MYH4-promoter activity and 
diameter of MYH4-expressing myotubes 
As before, treatment with dbcAMP significantly increased both 
MYH4-promoter activity (40%; P = 0.006) and average myotube 
diameter (30%; P = 0.006) relative to water. In contrast, treatment with 
Des(1–3) IGF-I for four days had no effect on MYH4-promoter activity (P 
= 0.823; Fig. 2a), but did increase average myotube diameter of MYH4- 
expressing myotubes (20%; P = 0.021; Fig. 2b) compared to its vehicle 
control, 0.1 M acetic acid, indicating a hypertrophic-like growth effect, 
although this was to a lesser degree compared to dbcAMP treatment. 
Fig. 1. Effect of dbcAMP on porcine MYH4-promoter activity and average myotube diameters. 
C2C12 cells were transfected with a ZsGreen expression plasmid driven by a porcine MYH4-promoter on day − 1 of differentiation, then treated with 1 mM dbcAMP 
or water (vehicle control) from day 0. (a) MYH4-promoter activity, determined as total fluorescence per well (ZsGreen) normalised to CMV-DsRed, was quantified 
every 24 h for three consecutive days from day 2 of differentiation. #P < 0.001 (time × treatment interaction). Data shown as means ± SEM, from four and seven 
wells at each time-point for control and dbcAMP-treated cells respectively. (b) Fluorescence images captured at days 2, 3 and 4 of differentiation. Magnification: 10X. 
Scale bar: 100 μm. (c) Average myotube diameter of MYH4-expressing myotubes was quantified at day 4 of differentiation following treatment from day 0 with water 
or 1 mM dbcAMP. Data shown as means ± SEM, from three fields of view per well using four wells for water and six wells for dbcAMP (n = 12 and n = 18 
respectively). ***P < 0.001. 
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3.3. Effect of 3,3’,5-Triiodo-L-thyronine (T3) on porcine MYH4-promoter 
activity and diameter of MYH4-expressing myotubes 
As expected dbcAMP treatment again resulted in a significant in-
crease in both MYH4-promoter activity (35%; P = 0.009) and average 
myotube diameter (32%; P = 0.003) relative to water. T3 treatment 
tended to increase MYH4-promoter activity (32%; P = 0.073; Fig. 2c) 
relative to the vehicle control, sodium hydroxide, and although this was 
not quite significant, this was possibly due to the low number of repli-
cates (n = 3). Average myotube diameter of C2C12 cells expressing 
MYH4 was not affected (P = 0.294; Fig. 2d) after four days of treatment 
with T3 compared to 0.1 M sodium hydroxide, indicating that T3 
potentially induced a change in the expression of the MyHC isoforms, 
but had no effect on myotube size. 
3.4. Effect of Dexamethasone (Dex) on porcine MYH4-promoter activity 
and diameter of MYH4-expressing myotubes 
As observed previously, treatment with dbcAMP significantly 
increased both MYH4-promoter activity (37%; P = 0.007) and average 
myotube diameter (34%; P = 0.009) relative to water. However, treat-
ment with dexamethasone (Dex) for four days had no effect on either 
MYH4-promoter activity (P = 0.187; Fig. 2e) or average diameter of 
MYH4-expressing myotubes (P = 0.69; Fig. 2f) compared to its vehicle 
control, ethanol. 
4. Discussion 
Here we have further characterised the porcine MYH4-promoter 
ZsGreen reporter system described previously [13,14] and for the first 
time report the response of the porcine MYH4-promoter to known 
Fig. 2. Effects of dbcAMP, Des(1–3) IGF-I, T3 and 
Dex on porcine MYH4-promoter activity and average 
myotube diameters. 
C2C12 cells were transfected with porcine MYH4- 
promoter-ZsGreen and CMV-DsRed expression plas-
mids on day − 1, then treated from day 0 of differ-
entiation with the following compounds and 
appropriate vehicle controls: (a, b) Des(1–3) IGF-I 
(20 ng/ml) or 0.1 M acetic acid, (c, d) T3 (10 nM) 
or 0.1 M sodium hydroxide, and (e, f) Dex (10 μM) or 
absolute ethanol. For each experiment, treatment 
with 1 mM dbcAMP or water was used as controls for 
the assay. Measurements were taken on day 4 of dif-
ferentiation for (a, c, e) MYH4-promoter activity, 
determined as total fluorescence per well (ZsGreen) 
normalised to CMV-DsRed, and (b, d, f) average 
myotube diameter of MYH4-expressing myotubes. 
Data shown as means ± SEM from n = 3 or 4 wells per 
treatment. To measure average myotube diameter, n 
= 3 or 5 fields of view per well were used for each 
treatment. To compare each treatment group with the 
appropriate vehicle control, data were analysed by 
either Student’s t-test (a, c, e) or one-way ANOVA, 
blocking for well (b, d, f). **P < 0.01.   
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anabolic and catabolic agents (dbcAMP, Des(1–3) IGF-I, T3, Dex). 
Treatment with dbcAMP significantly increased both average myo-
tube diameter of MYH4-expressing myotubes and MYH4-promoter ac-
tivity. This supports previous observations following treatment of 
C2C12 cells with dbcAMP from day 0 of differentiation leading to a 
dramatic upregulation of Myh4 mRNA and increased myotube size [48]. 
It also reflects both the muscle-specific hypertrophy and shift to a 
fast-glycolytic MyHC-IIB phenotype observed with BA treatment in pigs 
[10,11,15], cows [17,18], sheep [19], rats [20–23] and mice [14,24]. 
The reproducibility of the response to dbcAMP treatment was highly 
consistent, therefore dbcAMP and water (vehicle control) were used as 
positive controls for the MYH4-promoter activity and average myotube 
diameter measurements in subsequent experiments. 
Next, we investigated the effects of Des(1–3) IGF-I, an IGF-I 
analogue, on MYH4-promoter activity and myotube diameters. In the 
current study, Des(1–3) IGF-I treatment increased average myotube 
diameter but had no effect on MYH4-promoter activity. This indicates a 
hypertrophic-like growth response, but with no direct effect on MYH4 
expression, in agreement with previous reports of GH treatment in vivo 
[10,17]. Interestingly, a previous in vitro study showed that IGF-I 
treatment of C2C12 cells resulted in an increase in both Myh4 mRNA 
and murine Myh4-promoter activity [49]. They transfected C2C12 cells 
with a 3 kb murine MYH4-promoter construct and identified a putative 
IGF-I responsive element in the murine Myh4-promoter located 
approximately 1.2 kb upstream of the murine Myh4 gene [49]. This 
contrasts with our finding for the pig promoter, but it should be noted 
that Shanely et al. [49] treated C2C12 cells with high concentrations 
(250 ng/ml) of IGF-I in DM from day 0 for 2–4 days, which resulted in 
clear increases in differentiation that coincided with the increase in 
Myh4 promoter activity (and endogenous Myh4 mRNA). In fact there 
was no effect of IGF-I on Myh4 promoter activity at day 1 (24 h treat-
ment [49]), suggesting that the effect may be indirect (as a direct effect 
on transcription might be expected within 24 h) and may well relate to 
the observed induction of differentiation, rather than a direct effect of 
IGF-I per se. Indeed Shanely et al. [49] suggest that the responsiveness of 
the Myh4-promoter to IGF-I was via a T-cell factor/lymphoid enhancer 
factor-response element (Tcf/Lef-RE) that was conserved across species 
(rat, human, chimp). However, shorter promoter constructs lacking the 
putative Tcf/Lef-RE still responded to IGF-I and none of the signalling 
pathway inhibitors nor mutation of the putative Tcf/Lef-RE actually 
blocked the response to IGF-I [49]. It has also previously been reported 
that IGF-I KO mice have reduced body weight and reduced diaphragm 
muscle fibre size and fibre number, but no changes in fibre type pro-
portions [50], indicating that IGF-I has no effect on MyHC expression in 
mice in vivo. Hence, we believe the lack of response of the pig promoter 
to Des(1–3) IGF-I treatment is reflective of what happens in the pig and 
agrees with previous in vivo studies that also showed no change in MyHC 
mRNA expression when plasma IGF-I levels were increased by GH 
treatment [11]. 
Next, we determined the response of the porcine MYH4-promoter to 
treatment with T3. There was no effect of T3 on average myotube 
diameter of MYH4-expressing myotubes, but there was a tendency to 
induce MYH4-promoter activity. This indicates T3 treatment induces a 
fibre-type switching-like response by potentially altering the expression 
of the MyHC isoforms. The T3-induced increase in MYH4-promoter ac-
tivity agrees with the current in vivo literature. It has been reported that 
T3 treatment of rats (175 μg/kg) for 6 weeks increased the expression of 
MyHC-IIB protein (with decreased MyHC-IIX expression) in isolated fi-
bres from the posterior cricoarytenoid muscle [51]. Conversely, hypo-
thyroidism induced by thyroidectomy in adult rats resulted in a 
reduction in fast-twitch muscle fibres and an induction in slow-twitch, 
oxidative fibres [36,52]. Similarly, hypothyroidism in new-born pig-
lets, induced by the addition of inhibitory compounds (methimazole and 
iopanoic acid) to their feed, reduced the proportion of fast-twitch oxi-
dative/glycolytic type-II fibres and increased the proportion of slow 
oxidative type-I fibres [53]. Despite the consistency with in vivo 
observations reported here, a higher dose (30 nM) of T3 has previously 
been shown to reduce myotube diameters in C2C12 cells [54]. However, 
T3 treatment was added after two days of differentiation compared to at 
the onset of differentiation (day 0) in the present study, which may 
explain the discrepancy. 
Finally, the relatively short-term (i.e. 4 day) treatment with Dex (10 
μM) had no effect on either average myotube diameter or MYH4-pro-
moter activity. This was unexpected as Dex is known as a catabolic agent 
in vivo and is frequently used to induce atrophy and protein catabolism 
in C2C12 cells to model muscle wasting [39,47,55]. However, in those 
studies C2C12 cells had been differentiated for 3+ days prior to Dex 
treatment, whereas we treated myoblasts at the onset of differentiation 
(from day 0). It has also recently been reported that proliferating C2C12 
myoblasts transiently treated with Dex (10 μM) prior to differentiation 
actually enhanced myogenic differentiation, and increased both myo-
tube diameter and the abundance of total MyHC protein [56]. This 
suggests that proliferating myoblasts might respond differently to Dex 
treatment compared with differentiated myotubes. 
5. Conclusions 
Here we report the response of the porcine MYH4-promoter activity 
and MYH4-expressing C2C12 myotubes to known anabolic and catabolic 
agents (dbcAMP, Des(1–3) IGF-I, T3 and Dex) in vitro. For most treat-
ments (except Dex), these observations correspond to previous in vivo 
studies, and help to further understand the regulation of the porcine 
MYH4-promoter. This study also indicates that increased MYH4-pro-
moter activity is not always associated with muscle fibre hypertrophy. 
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